<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01470573</url>
  </required_header>
  <id_info>
    <org_study_id>MeRSO09</org_study_id>
    <nct_id>NCT01470573</nct_id>
  </id_info>
  <brief_title>Regenerative Medicine in Ocular Surface: Application of Cell Therapy for Ocular Surface Repair Using Progenitor Cells of Sclerocorneal Limbus Amplified ex Vivo</brief_title>
  <acronym>MeRSO09</acronym>
  <official_title>Regenerative Medicine in Ocular Surface: Application of Cell Therapy for Ocular Surface Repair Using Progenitor Autologous Cells of Sclerocorneal Limbus Amplified ex Vivo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Clinic per a la Recerca Biomédica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Progenitor limbo sclerocorneal cells have properties of proliferation and differentiation to
      corneal and conjunctival epithelium. This cells can be isolated and ex vivo expanded using
      cell culture technics that could permit the biological replacement of damaged ocular surface.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>6 months</time_frame>
    <description>visual acuity improvement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in appearance of ocular surface</measure>
    <time_frame>6 months</time_frame>
    <description>presence of corneal epithelium de novo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lack of scar tissue in ocular surface</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>decrease of preexisting corneal vascularization</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of corneal transparency</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>absence or decrease of corneal conjunctivalization</measure>
    <time_frame>6 months</time_frame>
    <description>the amount of caliciform cells using impression cytology will be compare between screening and 6 months visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Unilateral Limbic Insufficiency</condition>
  <arm_group>
    <arm_group_label>Progenitor Autologous Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Progenitor Autologous Cells of Sclerocorneal Limbus Amplified ex Vivo</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biological replacement corneal surface</intervention_name>
    <description>the expanded tissue will be applied to patient to replace the damaged ocular surface</description>
    <arm_group_label>Progenitor Autologous Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        principal Inclusion Criteria:

          -  Serious unilateral limbic insufficiency

          -  Normal ophthalmological clinical examination in the opposite eye (biopsied eye)

        Exclusion Criteria:

          -  one-eyed

          -  serious disorders in palpebral dynamics

          -  bilateral limbic insufficiency, immunological, systemic or local illness like toxical
             epidermic necrosis or pemphigoid

          -  breastfeeding or pregnancy

          -  positive serology of HIV, VLTH, HVC, HVB, CMV, Trypanosoma Cruzi or Treponema Pallidum
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo P Casaroli Marano, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Universitario Barraquer</name>
      <address>
        <city>Barcelona</city>
        <zip>08021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Microcirugía Ocular</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2011</study_first_submitted>
  <study_first_submitted_qc>November 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2011</study_first_posted>
  <last_update_submitted>December 7, 2012</last_update_submitted>
  <last_update_submitted_qc>December 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Sara Varea</investigator_full_name>
    <investigator_title>Clinical Research Manager</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

